# A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas

> **NCT02389244** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **UNICANCER** · enrollment: 163 (actual)

## Conditions studied

- Ewing Sarcomas
- Chondrosarcomas
- Osteosarcomas
- Chondroma
- CIC-Rearranged Sarcoma

## Interventions

- **DRUG:** Regorafenib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02389244
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-09
- **Primary completion:** 2024-10-25
- **Final completion:** 2026-03-11
- **Target enrollment:** 163 (ACTUAL)
- **Last updated:** 2025-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02389244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02389244, "A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02389244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*